Transmission blocking vaccine studies in leishmaniasis: I Lipophosphogly can is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis
نویسندگان
چکیده
منابع مشابه
Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum
Malaria transmission-blocking vaccines (TBVs) target the development of Plasmodium parasites within the mosquito, with the aim of preventing malaria transmission from one infected individual to another. Different vaccine platforms, mainly protein-in-adjuvant formulations delivering the leading candidate antigens, have been developed independently and have reported varied transmission-blocking a...
متن کاملTRIAL OF A NON-LIVING CRUDE VACCINE AGAINST ZOONOTIC CUTANEOUS LEISHMANIASIS
A field trial was canied outon60 volunteers selected in Yazd province, central Iran, with a vaccine containing killed promastigotes of L. major prepared by the Razi Institute, Hessarak. During these phase I studies which lasted for more than two years, we examined acceptable doses of the vaccine alone or mixed with BCG. The results so far indicate that 50 to 1000 µg of the vaccine alone can...
متن کاملTransmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax
Malaria transmission blocking (TB) vaccines (TBVs) directed against proteins expressed on the sexual stages of Plasmodium parasites are a potentially effective means to reduce transmission. Antibodies induced by TBVs block parasite development in the mosquito, and thus inhibit transmission to further human hosts. The ookinete surface protein P25 is a primary target for TBV development. Recently...
متن کاملLiposomes containing the imiquimod adjuvant as a vaccine in the cutaneous leishmaniasis model
Objective(s): Attempts to produce vaccines for leishmaniasis need adjuvants to trigger the kind of immune reaction required for protection. In this study, we examined the properties of the TLR7 agonist imiquimod, a vaccine adjuvant, making use of a live model of infection where the immune reactions could be identified prior to and following the challenge of infection. Materials and Method...
متن کاملWhat about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
The T helper cell type 1 (Th1) response is essential to resist leishmaniasis, whereas the Th2 response favors the disease. However, many leishmanial antigens, which stimulate a Th1 immune response during the disease or even after the disease is cured, have been shown to have no protective action. Paradoxically, antigens associated with an early Th2 response have been found to be highly protecti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: East African Medical Journal
سال: 2001
ISSN: 0012-835X
DOI: 10.4314/eamj.v78i2.9094